Related Experiment Video

Updated: Jul 16, 2026

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

Age-dependent pharmacokinetics of lamivudine in HIV-infected children

D M Burger1, G Verweel, N Rakhmanina

  • 1Department of Clinical Pharmacy, Radboud University Medical Centre, Nijmegen, The Netherlands. D.Burger@akf.umcn.nl

Clinical Pharmacology and Therapeutics
|March 3, 2007
PubMed

Insights

Pediatric human immunodeficiency virus (HIV) patients under 6 years old show significantly lower lamivudine exposure compared to older children. This age-related difference in drug exposure warrants further investigation for treatment outcomes and resistance.

Area of Science:

  • Pharmacology
  • Pediatric Infectious Diseases
  • Clinical Pharmacy

Background:

  • The standard pediatric dose of lamivudine for human immunodeficiency virus (HIV) infection is higher than the adult dose.
  • Limited data exist on the adequacy of lamivudine exposure in children at the recommended dosage.

Purpose of the Study:

  • To evaluate the pharmacokinetic (PK) parameters of lamivudine in pediatric patients with HIV.
  • To investigate the relationship between age and lamivudine exposure in children.

Main Methods:

  • Analysis of pharmacokinetic data from pediatric patients receiving lamivudine for at least two weeks.
  • Comparison of lamivudine PK parameters (Area Under the Curve, peak plasma concentration) between different age groups.

Main Results:

  • Lamivudine pharmacokinetic parameters were significantly associated with patient age.
  • Children younger than 6 years exhibited a 43% lower median Area Under the Curve and a 47% lower median peak plasma concentration compared to older children (P<0.001).

Conclusions:

  • Age is a critical factor influencing lamivudine exposure in pediatric HIV patients.
  • Further research is needed to understand the impact of reduced lamivudine exposure on treatment efficacy and resistance development in younger children.

More Related Videos

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...